Blockade of FGF signaling: Therapeutic promise for ovarian cancer

Cancer Biology and Therapy

Volumn 10, Issue 5, 2010, Pages 505-508

  Ivan, Mircea ^a,b   Matei, Daniela ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; FGFR; Isoform inhibitors; Ovarian cancer; Proliferation; Resistance

Indexed keywords

BIBF 1120; BRIVANIB; CA 125 ANTIGEN; E 7080; E7080; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM; TK I258; UNCLASSIFIED DRUG; UVOMORULIN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; DOWN REGULATION; GENE AMPLIFICATION; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; MISSENSE MUTATION; MUTAGENESIS; NOTE; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HUMANS; LIGANDS; OVARIAN NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77957103637     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.5.13023     Document Type: Note

References (51)

1. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996; 12:390-7.
2. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008; 33:233-7.
3. Zhang Y, Gorry MC, Post JC, Ehrlich GD. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene 1999; 230:69-79.
4. Cole C, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010; 10.
5. Jakobovits A, Shackleford GM, Varmus HE, Martin GR. Two proto-oncogenes implicated in mammary carcinogenesis, int-1 and int-2, are independently regulated during mouse development. Proc Natl Acad Sci USA 1986; 83:7806-10.
6. Moore R, et al. Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J 1986; 5:919-24.
7. Dickson C, Smith R, Brookes S, Peters G. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell 1984; 37:529-36. (Pubitemid 14079047)
8. Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997; 3:1137-40.
9. Schelling ME. FGF mediation of coronary angiogenesis. Ann N Y Acad Sci 1991; 638:467-9.
10. Harada H, et al. Localization of putative stem cells in dental epithelium and their association with Notch and FGF signaling. J Cell Biol 1999; 147:105-20.
11. Ikeya T, Hayashi S. Interplay of Notch and FGF signaling restricts cell fate and MAPK activation in the Drosophila trachea. Development 1999; 126:4455-63.
12. Kawakami Y, et al. WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo. Cell 2001; 104:891-900. (Pubitemid 32289281)
13. Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P. Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. Proc Natl Acad Sci USA 1995; 92:2268-72.
14. Shackleford GM, MacArthur CA, Kwan HC, Varmus HE. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc Natl Acad Sci USA 1993; 90:740-4.
15. Turner N, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70:2085-94.
16. Peng DF, Sugihara H, Mukaisho K, Tsubosa Y, Hattori T. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J Pathol 2003; 201:439-50.
17. Otto W, et al. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int J Cancer 2009; 125:2205-8.
18. Chen H, et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 2007; 27:717-30.
19. Byron SA, et al. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010; 117:125-9.
20. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61:3541-3.
21. Pollock PM, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26:7158-62.
22. Logie A, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005; 14:1153-60.
23. Antoniou AC, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82:937-48.
24. Thussbas C, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24:3747-55.
25. Spinola M, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23:7307-11. (Pubitemid 46202344)
26. Carstens RP, McKeehan WL, Garcia-Blanco MA. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol Cell Biol 1998; 18:2205-17.
27. Werner S, et al. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992; 12:82-8.
28. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20:563-9.
29. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 1994; 269:11620-7.
30. Vainikka S, et al. Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 1992; 11:4273-80.
31. Champion-Arnaud P, et al. Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor. Oncogene 1991; 6:979-87.
32. Miki T, et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992; 89:246-50.
33. Savagner P, Valles AM, Jouanneau J, Yamada KM, Thiery JP. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994; 5:851-62. (Pubitemid 24283766)
34. Scotet E, Houssaint E. Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2. Oncogene 1998; 17:67-76.
35. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997; 15:3059-65.
36. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001; 46:163-72.
37. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75:831-42.
38. Ricol D, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999; 18:7234-43.
39. Steele IA, et al. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001; 20:5878-87.
40. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 1994; 71:510-8. (Pubitemid 24338158)
41. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984; 20:743-55.
42. Wu C, et al. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation 2008; 76:193-205.
43. Birrer MJ, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25:2281-7.
44. Rosen A, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer 1993; 67:1122-5.
45. Yoneda J, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90:447-54. (Pubitemid 28160636)
46. Sako A, et al. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 2003; 115:113-20.
47. Barton DP, et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997; 3:1579-86.
48. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000; 97:8658-63.
49. Keyes K, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002; 62:5597-602.
50. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006; 23:1324-31. (Pubitemid 43946154)
51. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-29.